A global effort to understand the riddles of COVID-19 and cancer

Affiliations

¹ Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. vsubbiah@mdanderson.org.

Comment

Vivek Subbiah. Nat Cancer. 2020 Oct.

. 2020 Oct;1(10):943-945.

doi: 10.1038/s43018-020-00129-w.

¹ Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. vsubbiah@mdanderson.org.

No abstract available

Comment on

Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort.
Albiges L, Foulon S, Bayle A, Gachot B, Pommeret F, Willekens C, Stoclin A, Merad M, Griscelli F, Lacroix L, Netzer F, Hueso T, Balleyguier C, Ammari S, Colomba E, Baciarello G, Perret A, Hollebecque A, Hadoux J, Michot JM, Chaput N, Saada V, Hauchecorne M, Micol JB, Sun R, Valteau-Couanet D, André F, Scotte F, Besse B, Soria JC, Barlesi F. Albiges L, et al. Nat Cancer. 2020 Oct;1(10):965-975. doi: 10.1038/s43018-020-00120-5. Epub 2020 Sep 22. Nat Cancer. 2020. PMID: 35121871
SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer.
Rugge M, Zorzi M, Guzzinati S. Rugge M, et al. Nat Cancer. 2020 Aug;1(8):784-788. doi: 10.1038/s43018-020-0104-9. Epub 2020 Jul 31. Nat Cancer. 2020. PMID: 35122051

1. Albiges, L. et al. Nat. Cancer https://doi.org/10.1038/s43018-020-00120-5 (2020).
1. Rugge, M., Zorzi, M. & Guzzinati, S. Nat. Cancer 1, 784–788 (2020). - DOI
1. Alhalabi, O. & Subbiah, V. Trends Cancer 6, 533–535 (2020). - DOI
1. Alhalabi, O., Iyer, S. & Subbiah, V. EClinicalMedicine 23, 100374 (2020). - DOI
1. Lee, L. Y. W. et al. Lancet 395, 1919–1926 (2020). - DOI